Incyte Receives Approval For Tabrecta In Japan For Patients With Advanced NSCLC With METex14

Biopharmaceutical company Incyte Corp. (INCY) announced Monday that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved Tabrecta (capmatinib) for MET exon 14 skipping (METex14) mutation-positive advanced and/or recurrent unresectable non-small cell lung cancer (NSCLC).

from RTT - Biotech https://ift.tt/2ZiGcwD
via IFTTT